Drug Trial Radar · NCT05745727
A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels
Last checked: Nov 19, 2026Latest source record: Feb 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Mar 23, 2023
Primary completion
Aug 26, 2024
Study completion Feb 6, 2025
Sponsor
- Lead sponsor
- ProtalixIndustry
- Sponsor type
- Industry
- First posted
- Feb 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, double-blind, placebo-controlled, single ascending dose study in participants with elevated uric acid levels. This study will be conducted in approximately 64 adult male and female participants in the dose escalation phase.
Conditions
- Gout
Interventions
PRX-115Drug
Escalating doses of PRX-115 will be given in different cohorts i.e., Cohorts 1 through 8
PlaceboDrug
Escalating doses of Placebo will be given in different cohorts i.e., Cohorts 1 through 8
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events receiving PRX-115 compared to placeboTime frame: Day 0 - Day 85
- Number of participants with abnormal clinically significant clinical laboratory resultsTime frame: Day 0 - Day 85
- Number of participants with abnormal clinical vital signsTime frame: Day 0 - Day 85
- Number of participants with abnormal clinically significant results from physical examinationTime frame: Day 0 - Day 85
- Number of participants with abnormal clinically significant 12-lead electrocardiogram (ECG) parametersTime frame: Day 0 - Day 85
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
New Zealand Clinical Research
Grafton, Auckland, New Zealand
New Zealand Clinical Research
Christchurch, Christchurch, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.